NCT05253417View on ClinicalTrials.gov

The CANabidiol Use for RElief of Short Term Insomnia

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

July 7, 2023

Study Completion Date

July 7, 2023

Conditions
Sleep DisturbanceInsomniaInsomnia Type; Sleep DisorderInsomnia, TransientInsomnia Due to Anxiety and FearInsomnia Due to Other Mental Disorder
Interventions
DRUG

50 mg Cannabidiol (CBD)

For the study arm, '50 mg CBD' participants take two (2) CBD capsules and two (2) placebo capsules.

DRUG

Placebo

Participants take four (4) placebo capsules.

DRUG

100 mg Cannabidiol (CBD)

For the study arm, '100 mg CBD' participants take four (4) CBD capsules.

Trial Locations (2)

2037

Woolcock Institute, Glebe

5000

Fusion Clinical Research, Adelaide

Sponsors

Lead Sponsor

Bod Australia
All Listed Sponsors
collaborator

Woolcock Institute of Medical Research

OTHER

lead

Bod Australia

INDUSTRY

NCT05253417 - The CANabidiol Use for RElief of Short Term Insomnia | Biotech Hunter | Biotech Hunter